No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Livzon Pharmaceutical Group Inc., founded in Zhuhai, China, in 1985, is a prominent enterprise dedicated to the research, development, manufacturing, and global commercialization of a wide range of pharmaceutical products, including finished drugs, active pharmaceutical ingredients (APIs), and intermediate chemical compounds. The company's extensive therapeutic portfolio features numerous specialized medications, such as Ilaprazole enteric coated tablets for treating duodenal ulcers and reflux esophagitis, and Laprazole sodium injections designed to manage peptic ulcer hemorrhage. Other key pharmaceutical offerings include Leuprorelin Acetate Microspheres for injection, Urofollitropin injections for anovulation, Perospirone Hydrochloride for schizophrenia treatment, Anti-viral Granules for combating upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, sweating, and vertigo, and is also applied in managing symptoms for lung and stomach cancer patients. Beyond therapeutics, Livzon also excels in producing diagnostic reagents. Its diagnostic kits include those for detecting IgM/IgG antibodies to coronavirus, nucleic acid test kits for human immunodeficiency virus type 1, antinuclear antibody tests, interferon-gamma release assays, and rapid tests for Mycoplasma pneumoniae IgM antibodies. Furthermore, the company's comprehensive product line encompasses biochemical drugs, microbiological preparations, biologics, traditional Chinese medicinal preparations, pharmaceutical raw materials, and antibiotics.
www.livzon.com.cnNo one on the platform currently holds 1513.HK.
No tracked institution reports a position in 1513.HK as of their last filing.
No one on the platform has traded 1513.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 28.6% | 30.0% | 41.7% | — | — | — |
| Rev. Growth % | 1.8% | 2.7% | ||||
| Profit Margin % | 16.8% | 16.0% | 18.4% | |||
| Free Cash Flow Margin % | 21.1% | 16.1% | 14.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $11.1B | -9.1% | $2.22 | $2.11–$2.34 | — | 2 |
| 2027 | $11.7B | +5.8% | $2.42 | $1.93–$2.69 | — | 3 |
| 2028 | $12.1B | +3.1% | $2.62 | $2.30–$3.08 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-21 | $0.74 | $0.46 | -37.4% |
| 2026-04-23 | $0.82 | $0.74 | -9.7% |
| 2026-03-24 | $0.41 | $0.33 | -18.9% |
| 2025-10-23 | $0.66 | $0.57 | -13.4% |
| 2025-08-20 | $0.63 | $0.76 | +21.0% |
| 2025-04-23 | $0.75 | $0.76 | +1.3% |
| 2025-03-26 | $0.43 | $0.46 | +7.1% |
| 2024-10-23 | $0.63 | $0.54 | -14.4% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 1513.HKLivzon Pharmaceutical Group Inc. | $20.80 | -1.33% | $22.7B | — |
| 0013.HKHUTCHMED (China) Limited | $21.58 | +0.84% | $18.8B | — |
| 0512.HKGrand Pharmaceutical Group Limited | $4.91 | +0.51% | $17.2B | — |
| 0867.HKChina Medical System Holdings Limited | $10.90 | -2.07% | $26.5B | — |
| 0874.HKGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited |
| $13.20 |
| -0.68% |
| $32.8B |
| — |
| 2096.HKSimcere Pharmaceutical Group Limited | $11.25 | -1.23% | $28.9B | — |
| 2575.HKXuanzhubio-b | $8.30 | -2.12% | $4.3B | — |
Source: Financial Modeling Prep · peers by sector/industry